NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety
A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL antibody drug conjugate
Novel conditionally active ADCs (CAB ADCs): A novel class of molecules targeting solid tumors
Anti-Tumor Efficacy of BA3021
Anti-Tumor Efficacy of BA3011
Novel Conditionally Active Biologic anti-Axl ADC Demonstrates Anti-Tumor Efficacy and Improved Safety Profile
